Chromagen, Inc. has announced an expansion of its existing agreement with Merck and Co. to develop and supply a broad range of novel pharmacogenomic assays. Chromagen will utilize its High Performance Signal Amplification (HPSA) platform technologies and StarBright fluorophores to develop assays for evaluating cell signaling pathways and genes that are emerging biological targets in Read more about Merck And Chromagen Expand Collaboration[…]
Merck & Co., Inc. has announced that its wholly owned subsidiary, MC Subsidiary Corp., has acquired SIBIA Neurosciences, Inc. by completing its previously announced merger with SIBIA. MC Subsidiary Corp. completed in September a tender offer in which it purchased approximately 69 percent of the outstanding common stock of SIBIA for $8.50 per share. As Read more about Merck Completes Acquisition Of Sibia[…]
ImClone Systems Incorporated has received a $3 million payment from Merck KGaA for achieving a clinical development milestone under the Companies’ license agreement for ERBITUX(TM). Upon payment, ImClone Systems issued 150,007 shares of ImClone Systems’ common stock to Merck KGaA, representing the sale of these shares at a ten percent premium to market value as Read more about ImClone Receives $3 Million Payment From Merck[…]